Skip to content
Harvard T.H. Chan School of Public HealthHarvard T.H. Chan School of Public Health main site homepage
  • Quicklinks
    • About the School
    • Academics
    • Admissions
    • Research
    • Faculty
    • Student Life
    • News
    • Alumni
    • Frontiers
    • Make A Gift
Center for Communicable Disease Dynamics
Center for Communicable Disease Dynamics
  • Home
  • About
    • Director’s Welcome
    • About the Center
    • People
    • News & Events
      • Events Calendar
      • ID Epi Spring Seminar Series
      • 11th Annual Workshop to Increase Diversity in Mathematical Modeling and Public Health
    • Opportunities
    • Contact
  • Publications
  • COVID-19
  • Support CCDD

Publications

Filter Results

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment – California, December 2021-May 2022.

Author(s): Malden DE, Hong V, Lewin BJ, Ackerson BK, Lipsitch M, Lewnard JA, Tartof SY|Journal: MMWR Morb Mortal Wkly Rep|PMID: 35737591| June 2022
Nirmatrelvir/ritonavir (Paxlovid) is a combination protease inhibitor that blocks replication of SARS-CoV-2 (the virus that causes COVID-19) and has been…
Harvard T.H. Chan School of Public Health
677 Huntington Avenue Boston, MA 02115
+1 (617) 495‑1000
  • Harvard Chan Home
  • Contact Us
  • Harvard University Home
  • Make a Gift
  • Privacy Policy
  • Report Copyright Violation
  • Accessibility
Copyright © The President and Fellows of Harvard College